The Journal of Precision Medicine
PMLS
PMLS
BMS
BMS

About adminpmls2016

This author has not yet filled in any details.
So far adminpmls2016 has created 185 blog entries.

Tempus Sets Sights on Pathology Market With New Informatics, Research Network

2022-04-08T21:09:32-05:00April 8th, 2022|

Tempus has ventured into a new market segment with its recent introduction of Edge, a platform that provides pathologists with online access to artificial intelligence models to identify samples with potentially significant biomarkers with a single hematoxylin and eosin-stained slide. The platform is meant to help physicians decide whether to order genomic sequencing that [...]

New Research from the Caris Precision Oncology Alliance Finds Prognostic and Predictive Drug-Induced Gene Signatures for Colorectal Cancer Patients

2022-04-08T20:45:40-05:00April 8th, 2022|

- Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to revolutionize healthcare, to present findings that provide a deeper understanding that tumor expression of genes related to extent of drug exposure, stratified by p53 status, is associated with clinical outcomes on the common chemotherapeutic regimens used [...]

Blueprint Medicines Expands Trials of EGFR Inhibitors in NSCLC

2022-04-08T20:37:15-05:00April 8th, 2022|

Blueprint Medicines on Friday announced a clinical trial collaboration with AstraZeneca to study its EGFR inhibitors BLU-945 and BLU-701 in combination with AstraZeneca's Tagrisso (osimertinib) in non-small cell lung cancer. Blueprint will begin a trial cohort in its ongoing Phase I/II SYMPHONY trial to assess BLU-945 in combination with Tagrisso in patients with second-line [...]

Single-Cell Sequencing Study Uncovers Blood Cell Type-Specific Features

2022-04-08T20:32:18-05:00April 8th, 2022|

With the help of single-cell RNA sequencing, a University of California, San Francisco-led team teased out some of the processes and regulatory pathways behind systemic lupus erythematosus (SLE), profiling shifts in blood cell composition and the expression of distinct blood cell types in more than 150 individuals with the heterogeneous autoimmune condition. "Single-cell sequencing [...]

New Liquid Biopsy Method Infers RNA Expression From DNA Fragmentation Analysis

2022-04-08T20:30:02-05:00April 8th, 2022|

Researchers at Stanford University have developed a new method of detecting cancer from circulating tumor DNA (ctDNA) that combines DNA fragmentation analysis with deep sequencing to infer RNA expression profiles of tumor cells. The ability to predict RNA expression from ctDNA is a first for blood-based cancer detection, and has potential for diagnosis, prognosis, [...]

YESCARTA® RECEIVES U.S. FDA APPROVAL AS FIRST CAR T-CELL THERAPY FOR INITIAL TREATMENT OF RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

2022-04-03T09:52:15-05:00April 3rd, 2022|

Kite, a Gilead Company (Nasdaq: GILD), today announced the U.S. Food and Drug Administration (FDA) has approved Yescarta® (axicabtagene ciloleucel) CAR T-cell therapy for adult patients with large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line chemoimmunotherapy. Yescarta demonstrated a clinically meaningful and statistically significant improvement [...]

BabySeq Newborn Screening Project Aims For Increased Diversity in Second Phase

2022-04-03T09:46:26-05:00April 3rd, 2022|

BabySeq, the next-generation sequencing-based universal screening program for newborns, is gearing up for a second, expanded study. The lead researchers said they want the four-year, $5.1 million grant to help address a lack of diversity in the first cohort. The original BabySeq cohort was not diverse and thus the findings are not generalizable, according [...]

SomaLogic Previews New Products, Global Expansion Coming in 2022

2022-04-03T09:43:53-05:00April 3rd, 2022|

SomaLogic said this week that it expects to launch more than 10 new products over the course of the coming year, including diagnostic assays and distributed research kits. On a conference call with investors following the release of the firm's fourth quarter and full-year 2021 financial results, company officials previewed 2022 for the Boulder, [...]

Go to Top